What you need to know

  • CTC STOP is a clinical trial linked to our London Center of Excellence, funded in partnership with Movember, which is dedicated to finding the best treatments for each individual man.
  • The trial team are testing whether clues in men’s blood called ‘CTCs’ can help clinicians tell whether chemotherapy is working sooner than current tests, so that men can be moved onto more effective treatments sooner.
  • The trial could result in taking us another step closer to personalizing men’s treatment, to make sure they have the maximum benefit to men possible.

The trial enabled my medical team to make a decision about my treatment. If I hadn’t been taking part in CTC STOP, I may have continued to be treated with Docetaxel when another drug would have been more helpful.

- Nick, a participant on CTC STOP.

What they want to find out

Each man is completely unique, and so is his cancer. That means a treatment which works well for one man may not have the same effect on another. We want to make treatments more precise, so that they're as effective for each man as possible. Our London Centre of Excellence, funded in partnership with Movember, is dedicated to this mission, and includes the CTC STOP trial.

CTC STOP is based on previous research that shows that when men’s treatment is working, the number of circulating tumour cells (CTCs) in their blood goes down. Professor Johann de Bono and his team at the Institute of Cancer Research want to make the most of this, and test whether they can use CTCs to monitor men’s response to chemotherapy for their advanced prostate cancer. They hope CTCs will be a quicker way to tell whether treatment has stopped working, than standard tests like CT scans. This should help to maximize the benefits of treatments, while reducing time spent on drugs that are no longer working.  

How are they doing it

The trial plans to recruit around 200 men, all of which are on chemotherapy to treat their advanced prostate cancer. For half of these men, the team will take blood tests to monitor their CTC’s, and will use this information to make decisions about their treatment. The other half of the men will have their treatment monitored by tests that are standard at the moment. By the end of the study, the team will compare how well the two groups of men have been fairing on their treatment, to work out whether CTCs can be used to improve outcomes and treatment for advanced prostate cancer.

Progress so far

So far, the team have started to recruit men to the trial. Some of these men have already benefited from the research in the trial, like Nick, whose treatment plan was altered based off his CTC results. But before the team can confidently work out if CTCs should replace current ways to monitor treatment, they’ll need to continue recruiting men and collecting data. 


How to get involved with this trial

This trial is still looking for men to take part. You can read the information below to see if you may be suitable to take part in this study, and contact your medical team for full details on whether you can take part.

If you’d like support with deciding whether taking part in a clinical trial is right for you, you can speak to your medical team or contact our Specialist Nurses on 0800 074 8383

Who can take part

You may be eligible to take part in this study if you have metastatic, hormone therapy-resistant prostate cancer, which has only spread to the bone.

Who can’t take part

You would not be eligible to take part if you have:

  • Any prior chemotherapy for your hormone therapy-resistant metastatic prostate cancer (patients who have received chemotherapy for hormone-sensitive prostate cancer would still be able to take part in the trial)
  • Any cancer metastases that are outside the bone
  • Current symptomatic cord compression requiring surgery or radiation therapy. (Once the patient is successfully treated the patient will be considered eligible for the study).

For full inclusion and exclusion criteria speak to your medical team.

Where the trial is taking place

  • Royal Marsden, Sutton
  • Western General Hospital, Edinburgh
  • Velindre Cancer Centre
  • University College Hospital, London
  • Musgrove Park Hospital, Taunton
  • Derriford Hospital, Plymouth
  • St George's Hospital, Tooting
  • E&NHTrust - Lister Hospital, Stevenage
  • E&NHTrust - Mount Vernon, Middlesex
  • Royal Lancaster Infirmary, UHMB
  • Royal Shrewsbury Hospital
  • Belfast City Hospital
  • The Beatson, Glasgow
  • UHB Bristol

Please note, We try to keep this information as up to date as possible, but there may be times when study details have changed and we haven’t updated our web information. Speak to your medical team, or our Specialist Nurses, for the most up to date information on prostate cancer clinical studies.

Grant information

Reference - CEO13_2-002
Researcher - 
Professor Johann de Bono
Institution – Institute of Cancer Research, London 
Award – Part of the Movemeber Centre of Excellence, awarded £5,204,881